The Exeltis subsidiary in the United States has just launched a new prenatal supplement to meet the ever-growing need for supplements with a greater iron content. The supplement in question is Vitafol Fe+, from the Vitafol food supplement family; it contains 90 mg of iron, one of the most deficient vitamins during pregnancy.
David Moreno, co-founder of the company Hawkers, has not only managed to capture the hearts of the thousands of people who buy his glasses, he also managed to move us with his story as a guest at the last View 360° that took place at Madrid office. He spoke to us about his beginnings, the idea which started the business but most of all about how he and his team have learned to look at social networks from another perspective, to make the most of them to develop their brand and end up today the company which has the second highest amount of likes on Facebook in the world. Without investors or large budgets, simply by following his motto “All or nothing”, in a record time of barely two years, they managed to surpass a turnover of 15 million and make his glasses an international success, including with NBA team the Lakers.
Exeltis has just launched an innovative application that brings the company to all health professionals’ fingertips. ExeltisME was created with the aim of informing health professionals of the medicinal products it offers through its network of over 35 affiliates across four continents, all at the click of a button. In the near future, all the information will also be made available to the general public.
Exeltis Indian subsidiary, Ordain, has just acquired the women’s health division of Alkem Laboratories, Fertica, which specialises in fertility products. Exeltis thus strengthens its position in a market that presents great business opportunities. Its organisational structure and its strengths will make it a leader in the country’s pharmaceutical market.
Consumer recognition of the qualities of Inofolic led to Exeltis Poland product being bestowed the "Discovery 2015" award in this country in the category of supplements designed for women when planning for pregnancy. This award honours the most innovative and highest quality products and services, as well as those which, thanks to their advertising campaigns, have been identified as national leaders by consumers. This award makes this affiliate one of the fastest growing companies in gynaecology in Poland.
Recedo is the name of the new product launched by the Exeltis USA dermatology division in May.It is an advanced formula topical gel indicated for treating hypertrophic and keloid scars caused by burns, surgery or trauma. This product not only helps to improve the appearance of scars, but it also relieves itching and discomfort.
Exeltis, a branch of the pharmaceutical Grupo Chemo, has acquired 100% of the Turkish pharmaceutical Embil.The deal is the biggest acquisition ever by Exeltis abroad.It also represents the entry of the Spanish company into Turkey, a market of great potential due to its population and its high proportion of young people (nearly a third are under 15 years of age).
The deal is part of Exeltis's Strategic Plan that aims to consolidate its international development. Following its acquisitions in India, Indonesia and the United States, the company already has a presence in more than 40 countries, thanks to 30 subsidiaries in key markets and its extensive global manufacturing network in Europe, America and Asia.
With a presence in over 40 countries, Exeltis continues to forge ahead from one country to the next in its aim to reach all corners of the world while providing therapeutic solutions to millions of people. In Asia, we are already in China, the Philippines, Malaysia, Singapore, India, Indonesia and Thailand, and we are now able to add Exeltis Vietnam to that list.
Quinnova Pharmaceuticals LLC, an affiliate of Exeltis™, today announced the launch of its recently U.S. Food and Drug Administration approved ECOZA™ (econazole nitrate) topical foam, 1%. ECOZA™ FOAM is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.